Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective

NCT07323394 | Not Yet Recruiting

• 1 other identifier: PROxy96AD
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.

Conditions

Atopic Dermatitis; Eczema Atopic Dermatitis; Eczema; Caregiver; Burden

Keywords

atopic dermatitis; quality of life; real-world

Outcome Measures

Primary Outcomes (1)

• To estimate work productivity loss in caregivers of children with mild or moderate atopic dermatitis.

  Using the Work Productivity and Activity Impairment questionnaire. This questionnaire provides a quantitative measure of impairment over the last 7 days and includes four metrics: absenteeism (work time missed because of health issues during the past 7 days), presenteeism (impairment while working due to health issues during the past 7 days), overall work productivity loss (combination of absenteeism and presenteeism), and activity impairment.

  At recruitment

Secondary Outcomes (1)

• To estimate family burden of mild to moderate atopic dermatitis in children, as reported by caregivers

  At recruitment

Study Arms (1)

Caregiver of child with atopic dermatitis

Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis

Other: No Intervention: Observational Cohort

Interventions

No Intervention: Observational Cohort OTHER

No specific intervention is assess in this study. Observational cohort.

Caregiver of child with atopic dermatitis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis

You may qualify if:

• Aged ≥18 years;
• Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;
• Able to read and understand French or English;
• Willing and able to provide written informed consent.

You may not qualify if:

• Caregivers whose child has been diagnosed with severe atopic dermatitis ;
• Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);
• Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;
• Other parent or caregiver within the household of the child with atopic dermatitis.

Sponsors & Collaborators

• PeriPharm: lead

MeSH Terms

Conditions

Dermatitis, Atopic; Eczema

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Central Study Contacts

Jean Lachaine, Ph. D.

CONTACT

514-731-8207; jean.lachaine@peripharm.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 22, 2025
• First Posted: January 7, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: January 23, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share